Release date: 2015-01-21
Status & Development
According to statistical analysis, 2/3 of medical decisions rely on diagnostic information, but the diagnostic income accounts for only 1% of total medical expenses. It is believed that with the advancement of diagnostic technology in the future, it will have a positive effect on disease prevention, diagnosis and treatment. Especially for emerging countries, diagnostic reagents are still in a period of rapid development, and there is a huge space for future development of the industry. At present, the in vitro diagnostic reagent industry as a whole is at a high point of the cycle boom. In the future, China's in vitro diagnostic market will still maintain a growth rate of 15% to 20%. Pharmaceutical companies are facing good development opportunities, and pharmaceutical companies can further expand through investment in mergers and acquisitions. Market share of in vitro diagnostic reagents.
China's in vitro reagent market is large, and its market potential is greater
The country's in vitro diagnostic reagent industry already has a certain market size and foundation, and is entering the growth stage from the industrial introduction period. The market has good development prospects. From 2007 to 2014, the growth rate of China's in vitro diagnostic market was significantly higher than the global average. At present, the monopolistic advantages of imported reagents and diagnostic instruments are being broken and restricted by ethnic products. The development of China's in vitro diagnostic reagent industry has generally shown The characteristics are that the market is large and the market potential is greater.
The above picture shows the overall scale of China's in vitro reagent industry from 2007 to 2014, with an average compound growth rate of 16%. China's in vitro diagnostic reagent industry is relatively small. China's population accounts for more than one-fifth of the world's population, but the share of in vitro diagnostic reagents accounts for only 4% of the world's total. The annual per capita use of in vitro diagnostic products in China is 1.5. The US dollar, while the per capita use of developed countries is 25 to 30 US dollars.
North America is the largest market for in vitro diagnostic reagents
According to the global market for in vitro diagnostic reagents, the largest market for in vitro diagnostic reagents is in North America, accounting for 44%, while Western Europe accounts for 30%, and Japan and China in Asia account for 11% and 2% respectively.
Market segments
In vitro diagnostic reagents include blood, biochemistry, immunity, molecular biology, bacteria, POCT and other aspects. From the global in vitro diagnostic reagent market, according to the diagnostic method subdivision, immunodiagnosis, clinical biochemical diagnosis and molecular diagnosis occupy the top three, the clinical biochemical diagnosis and immunodiagnosis market in developed countries is close to maturity, and POCT and molecular diagnosis are the main growth in the diagnostic market. point. China's immunodiagnostic reagents and clinical biochemical diagnostic reagents are the two major in vitro diagnostic reagent markets.
Molecular diagnosis or medical mergers and acquisitions hotspots
According to the above figure, the market for immunodiagnosis and biochemical diagnosis is close to saturation, and molecular diagnosis will become a hot spot in the in vitro diagnostic reagent market.
Although molecular diagnosis is currently only 5%, molecular diagnosis will usher in a high growth period. Molecular diagnosis not only plays an important role in traditional infectious diseases, screening and diagnosis of genetic diseases, and detection of transplant matching, but also is widely used in the fields of individualized diagnosis and treatment of cancer, expensive drug treatment monitoring, and drug metabolism genomics research.
Molecular diagnosis is a kind of in vitro detection. The detection target is at the level of genetic material, and molecular biology methods are applied to detect changes in the structure or expression level of genetic material in patients, and then to make a diagnosis technique. Compared with other branches of in vitro diagnosis, biochemical diagnosis and immunodiagnosis, it is more specific and precise. With the transformation of medical models and the continuous development of individualized medications, the medical testing community urgently needs rapid, accurate and specific detection methods, and molecular diagnostics has a unique advantage, making personalized diagnosis and targeted therapy possible.
With the technological advancement of genetic testing, the global molecular diagnostics market is growing rapidly. In 2015, global molecular diagnostic products sales are expected to exceed $8 billion. In recent years, the global molecular diagnostics market has reached a growth rate of 10%, while the Chinese molecular diagnostics market has grown at an annual rate of more than 20%, twice the global level. The molecular diagnostics industry will remain in a state of high prosperity for a long time. At present, China's large and small molecular diagnostic companies have joined the market battle, Shenzhen Huada, Daan Gene, Kehua Biological, Shanghai Zhijiang, Beijing Boao, Xiamen Aide, Hunan Shengxiang, Fuzhou Taipu, Guangzhou Anbi Equality and many companies have seized the molecular diagnostic market.
The market for in vitro diagnostic reagents is promising. Global pharmaceutical companies are engaged in mergers and acquisitions, and are actively involved in the field of in vitro diagnostic reagents. Pharmaceutical companies that have a seat in the field of in vitro diagnostic reagents are also frequently acquiring and expanding the product line of diagnostic reagents to increase the company's in vitro diagnostic reagents. Market share. Among them, molecular diagnostic reagents will become a hotspot in the in vitro diagnostic reagent market.
Four major mergers and acquisitions
Roche's $450 million acquisition of IQuum into the molecular diagnostic care market >
In April 2014, Roche Pharmaceuticals spent $450 million to acquire IQuum, Inc., which focuses on developing instant care products for the molecular diagnostics market. The acquisition has enabled Roche to quickly enter the market segment for immediate diagnosis of molecular diagnostics. At the same time, Roche Pharmaceuticals also acquired IQuum's Liat system, which enables the caregiver to conduct rapid molecular diagnostic tests at a patient's care site with minimal training.
  Â
Illumina acquires Myraqa and enters the clinical market
In July 2014, Illumina acquired Myraqa and entered the clinical market. Myraqa is a company focused on in vitro diagnostics, especially companion diagnostics, with a focus on regulatory strategies and application support, including premarketing approvals, pre-submissions, experimental device exemptions, 510(k), denovo510(k), and EU technical documents. The acquisition is a way for Illumina to pave the way for the application of genomics technology in regulated markets, including next-generation sequencing, while pushing the standards for clinical use.
  Â
Beijing Lidman acquires Desai Diagnostic System
Beijing Lidman Biochemical Co., Ltd. acquired a partial shareholding in Desai Diagnostic System and Desai Diagnostics. Upon completion of the transaction, Lidman will hold 25% and 31% of each of Desai and Desai products. The acquisition is Lidman's active expansion of its market share in biochemical diagnostic reagents. Â Â Â
Market forecast, potential big "buyers" surfaced at any time
The market predicts that there is also a potential big “buyer†that will surface at any time. Danaher has indicated that it is ready to acquire again. Since the acquisition of Beckman Coulter three years ago, Danaher has been holding a wait-and-see attitude in the life sciences market. Currently, Danaher has $12 billion in funds available for acquisition. Company officials said they plan to use at least part of their money to expand their life sciences and diagnostic product lines. At an investor conference, Danaher CEO Larry Culp said, “Danach will continue to actively implement acquisitions throughout 2014 and beyond. There is currently no clear gap between Danaher’s life sciences and diagnostics product lines. Need to be addressed, in the process of pursuing the transaction, we are in an offensive position. By taking advantage of existing businesses, including Beckman Coulter, AB SCIEX, Leica, to increase the value of strategic acquisitions."
Source: Bio-Exploration
Soft Comfortable Dressing,Breathable Dressing,Silicone Dressing,Custom Hydrocolloid Dressing
Zhende Medical Co.,Ltd , https://www.zdmedicalproducts.com